Episodic Breathlessness in Patients with Advanced Cancer: Characteristics and Management

被引:6
|
作者
Mercadante, Sebastiano [1 ,2 ,3 ]
机构
[1] La Maddalena Canc Ctr, Anesthesia & Intens Care & Pain Relief & Palliat, Via San Lorenzo 312, I-90145 Palermo, Italy
[2] SAMO, Home Palliat Care Program, Palermo, Italy
[3] Univ Palermo, Pain Therapy, Palermo, Italy
关键词
TRANSMUCOSAL FENTANYL CITRATE; RANDOMIZED CONTROLLED-TRIAL; BUCCAL TABLET; DOUBLE-BLIND; ADVANCED DISEASE; LUNG-CANCER; DYSPNEA; PAIN; HOME; PREVALENCE;
D O I
10.1007/s40265-018-0879-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this review is to present the way in which episodic breathlessness (EB) has been recognized over the years, with regard to definition, characteristics, and management of these acute episodes that have serious consequences for patients. EB is characterized by a sudden increase in intensity of dyspnea over a short duration of time, leading to high levels of anxiety. A significant aggravation of dyspnea may occur in patients with a background of dyspnea or intermittently even without basal breathlessness. Often, known precipitating factors may trigger EB. Flares of breathlessness are accompanied by degrees of psychological distress, although it is unclear whether psychological factors may precede or be induced by EB. In any case, there is a reinforcing circuit. The duration of EB ranges from 10-30 min. Given the specific temporal pattern, requiring rapid intervention, substances with a short onset of action are suitable to overlap this phenomenon. Short-onset opioids could provide a clinical effect overlapping the onset and duration of an episode, resembling what has been largely reported for breakthrough pain. Although data are still insufficient to suggest specific recommendations, strategies such as avoiding exertion, pacing or using devices, or keeping calm have been described. Few controlled studies have investigated the effects of different formulations of opioids. Some data were gathered from studies assessing the pre-emptive use of rapid onset opioids, such as transmucosal preparations of fentanyl, followed by a provocative test, while other studies attempted to reproduce real-life conditions, given as needed. All these trials were insufficiently powered to address the efficacy of fentanyl products over oral morphine or placebo, reflecting the difficulties in patient recruiting and finalizing the studies. Strategies to prevent the occurrence of EB should be taken into consideration, including optimization of the condition of persistent dyspnea or treating psychologic or environmental causes.
引用
收藏
页码:543 / 547
页数:5
相关论文
共 50 条
  • [1] Episodic Breathlessness in Patients with Advanced Cancer: Characteristics and Management
    Sebastiano Mercadante
    [J]. Drugs, 2018, 78 : 543 - 547
  • [2] Epidemiology and Characteristics of Episodic Breathlessness in Advanced Cancer Patients: An Observational Study
    Mercadante, Sebastiano
    Aielli, Federica
    Adile, Claudio
    Valle, Alessandro
    Fusco, Flavio
    Ferrera, Patrizia
    Caruselli, Amanda
    Cartoni, Claudio
    Marchetti, Paolo
    Bellavia, Giuseppe
    Cortegiani, Andrea
    Masedu, Francesco
    Valenti, Marco
    Porzio, Giampiero
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2016, 51 (01) : 17 - 24
  • [3] Opioids for management of episodic breathlessness or dyspnea in patients with advanced disease
    Luis Cabezón-Gutiérrez
    Parham Khosravi-Shahi
    Sara Custodio-Cabello
    Francisco Muñiz-González
    Maria del Puerto Cano-Aguirre
    Soledad Alonso-Viteri
    [J]. Supportive Care in Cancer, 2016, 24 : 4045 - 4055
  • [4] Opioids for management of episodic breathlessness or dyspnea in patients with advanced disease
    Cabezon-Gutierrez, Luis
    Khosravi-Shahi, Parham
    Custodio-Cabello, Sara
    Muniz-Gonzalez, Francisco
    del Puerto Cano-Aguirre, Maria
    Alonso-Viteri, Soledad
    [J]. SUPPORTIVE CARE IN CANCER, 2016, 24 (09) : 4045 - 4055
  • [5] Background and episodic breathlessness in advanced cancer patients followed at home
    Mercadante, Sebastiano
    Fusco, Flavio
    Caruselli, Amanda
    Cartoni, Claudio
    Masedu, Francesco
    Valenti, Marco
    Aielli, Federica
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (01) : 155 - 160
  • [6] Management of refractory breathlessness in patients with advanced cancer
    Simon, Steffen T.
    Bausewein, Claudia
    [J]. WIENER MEDIZINISCHE WOCHENSCHRIFT, 2009, 159 (23-24) : 591 - 598
  • [7] Characterizing Episodic Breathlessness in Patients with Advanced Disease
    Weingaertner, Vera
    Bausewein, Claudia
    Higginson, Irene J.
    Scheve, Christine
    Murtagh, Fliss E. M.
    Voltz, Raymond
    Simon, Steffen T.
    [J]. JOURNAL OF PALLIATIVE MEDICINE, 2013, 16 (10) : 1275 - 1279
  • [8] Management of Breathlessness in Patients With Advanced Cancer: A Narrative Review
    Lok, Chan Wing
    [J]. AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE, 2016, 33 (03): : 286 - 290
  • [9] Episodic Breathlessness in Patients With Advanced Disease: A Systematic Review
    Simon, Steffen T.
    Bausewein, Claudia
    Schildmann, Eva
    Higginson, Irene J.
    Magnussen, Helgo
    Scheve, Christine
    Ramsenthaler, Christina
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2013, 45 (03) : 561 - 578
  • [10] Characteristics of episodic breathlessness as reported by patients with advanced chronic obstructive pulmonary disease and lung cancer: Results of a descriptive cohort study
    Weingaertner, Vera
    Scheve, Christine
    Gerdes, Verena
    Schwarz-Eywill, Michael
    Prenzel, Regina
    Otremba, Burkhard
    Muehlenbrock, Juliane
    Bausewein, Claudia
    Higginson, Irene J.
    Voltz, Raymond
    Herich, Lena
    Simon, Steffen T.
    [J]. PALLIATIVE MEDICINE, 2015, 29 (05) : 420 - 428